ProKidney Corp.

$0.79
(as of Apr 17, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for ProKidney Corp.

Stock Price
$0.79
Ticker Symbol
PROK
Exchange
NASDAQ

Industry Information for ProKidney Corp.

Sector
Healthcare
Industry
Biotechnology

Company Description for ProKidney Corp.

Website
https://prokidney.com
Country
USA
Full Time Employees
204

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Fundamentals for ProKidney Corp.

Market Capitalization
$1,811,825,408
EBITDA
$-172,920,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.62
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
129,536,000
Percent Owned by Insiders
29.09%
Percent Owned by Institutions
44.37%
52-Week High
52-Week Low

Technical Indicators for ProKidney Corp.

50-Day Moving Average
200-Day Moving Average
RSI
45.47
ATR
0.15

Analyst Ratings for ProKidney Corp.

Strong Buy
4
Buy
0
Hold
3
Sell
0
Strong Sell
0

News About ProKidney Corp.

Mar 27, 2025, 12:01 PM EST
There's no doubt that money can be made by owning shares of unprofitable businesses. See more.
Mar 21, 2025, 9:55 AM EST
ProKidney Corp. See more.
Mar 17, 2025, 7:30 AM EST
Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, and securing $140 million of equity to extend cash runway into mid-2027In Q4 2024, the FDA confirmed in a Type B meeting that the accelerated approval pathway is available for rilparencel if an acceptable surrogate endpoint, which may include eGFR slope, is used; additional details expected in mid-2025Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025; interim data from June 2024 showed kidney function stabilization for 18 months in patients with advanced CKD and diabetesEnded the fourth quarter with $358 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 See more.
Mar 17, 2025, 7:30 AM EST
ProKidney See more.